Parvus Announces Collaboration with AbbVie
South San Francisco, CA, March 20, 2024 — The collaboration will combine AbbVie’s expertise in Immunology with Parvus’ innovative Navacim™ regulatory T cells (Treg) immune tolerization platform technology to develop therapies for Inflammatory Bowel Disease Parvus Therapeutics announced today that…